Page 125 - NobleCon20-Book-Project

NRx Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS NRXP

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (4.41) (6.00) (7.05) (3.02) (20.48)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (4.33) (6.53) (7.90) (1.62) (20.38)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 7.32 3.79 5.26 4.46 4.46
Cash & Short Term Investments 4.60 1.32 1.90 1.65 1.65
% of Assets 63% 35% 36% 37% 37%
Current Assets -Total 6.88 3.35 4.88 4.11 4.11
% of Assets 94% 88% 93% 92% 92%
Total Liabilities 19.05 18.86 23.66 23.28 23.28
% of Assets 260% 498% 449% 522% 522%
Current Liabilities - Total 19.05 18.86 23.66 20.30 20.30
% of Assets 260% 498% 449% 455% 455%
Long Term Debt NA NA NA 2.99 2.99
% of Assets NM NM NM 67% 67%
Total Equity (11.73) (15.07) (18.39) (18.82) (18.82)
% of Assets -160% -398% -349% -422% -422%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.19) (3.67) (2.56) (2.31) (11.73)
Net Cash Flow - Investing 0.00 NA NA NA 0.00
Net Cash Flow - Financing (1.12) 0.40 3.14 2.05 4.47

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference